(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a ...
GlobalData on MSN23h
Amgen speaks out about bone density concerns with obesity drugAmgen’s stock fell 7% after an analyst posted a note on MariTide’s influence on bone density which was noticed in a data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback